Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

The company announced promising results from its LOTIS-7 Phase 1b trial, where the combination of ZYNLONTA and glofitamab showed a 93.3% overall response rate in patients with relapsed or refractory ...

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ...

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) ...

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator ...

The study evaluated 41 patients for safety and 30 for efficacy across two ZYNLONTA dose levels (120 μg/kg and 150 μg/kg) in combination with glofitamab.

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased ...

Discover ADC Therapeutics' Q1 2025 earnings insights, with strong progress in ZYNLONTA trials, high response rates, and a solid cash runway.

Management estimated ZYNLONTA’s peak revenue in the U.S. at $600 million to $1 billion, contingent on regulatory approval and compendia listing. For LOTIS-5, updated data are expected by the end ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!